NCT05477524: An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
- State
- Completed
- Phase
- Phase 3
- People
- 12,546 taking part
- Started
- 4 Aug 2022
- Primary completion
- 7 Jan 2026
- Arms
- VLA15 Lot 1 (3-dose primary vaccination series and booster dose), VLA15 Lot 2 (3-dose primary vaccination series and booster dose), VLA15 Lot 3 (3-dose primary vaccination series and booster dose)
- Results
- None posted
- 28 Jul 2022: Trial registered
- 4 Aug 2022: Trial started
- 7 Jan 2026: Trial completed